Immune checkpoint inhibitors (ICI) target key points in the immune system’s tolerance to tumors in order to enhance the anti-tumor response, such as cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death 1 protein (PD1) and its ligand programmed cell death 1 ligand 1 (PDL1) [1,2,3]. This evidence concerns the gene CD274 and neoplasm.